Urea Cycle Disorder Market

Global Urea Cycle Disorder Market Size, Trends & Analysis - Forecasts to 2028 By Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Others), By Enzyme Deficiency Type (Ornithine Transcarbamylas (OTC), Argininosuccinate Synthetase (citrullinemia) (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1), N-acetylglutamate Synthase (NAGS)), By Route of Administration (Oral, Injectable), By Region (North America, Asia Pacific, Central & South America, Europe, Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare
Format
  • ms word
  • ms excel
  • ms ppt
  • pdf
This report was recently updated on May 12 2024 with the latest and most recent market numbers

Global Urea Cycle Disorder Market Size

The Global Urea Cycle Disorder Market is expected to be valued at USD 2.56 billion in 2023, and is projected to grow at a CAGR of 3.6% from 2023 to 2028.

The severity of the urea cycle disorder (UCD) is determined by the defective amount of protein. The presence of well-established companies, an increase in R&D spending by industry titans in the pharmaceutical sector and collaborations between pharmaceutical and biotech companies and research institutes are some of the factors influencing the global market for urea cycle disorders.

Rising prevalence of urea cycle disorders amongst both new-borns and geriatric patients is expected to propel the market. For instance, according to the National Library of Medicine’s report of 2021, out of every 35,000 live births, there are 113 new cases of urea cycle disorders in the United States. There are more than 149 patients in EU member states suffering from some form of the urea cycle disorder. According to a November 2021 StatPearls article, the prevalence of urea cycle disorder brought on by ornithine transcarbamylase deficiency is thought to be 1 in 140,000 individuals.

Furthermore, the market is expected to propel rapidly owing to strategic initiatives including collaborations, expansions, and acquisitions. For instance, in October 2021, Thoeris GmbH and Boehringer Ingelheim established a collaboration and licence agreement to research cutting-edge, first-in-class treatments for people with urea cycle diseases (UCDs). Such a collaboration will aid participants in utilising their knowledge and increasing the range of products they offer, thereby boosting the market.

As a result of these factors, it is anticipated that the global market would experience considerable growth throughout the study period. However, it is anticipated that the high cost of therapies may restrain market expansion during the forecast period.

global urea cycle disorder market

Global Urea Cycle Disorder Market: By Treatment Type

The sodium phenylbutyrate segment is anticipated to be the fastest-growing segment in the market from 2023-2028, as it offers additional ammonia removal pathways and lowers ammonia levels. Furthermore, other factors associated with the growth of the segment is the increasing number of research projects linked with the usage of sodium phenylbutyrate and increasing awareness about the added advantages. For instance, in February 2022, the United States Patent and Trademark Office (USPTO) granted a new patent to Relief Therapeutics Holding SA and its joint venture partner, Acer Therapeutics, for specific claims regarding ACER-001 (sodium phenylbutyrate), who were conducting studies on ACER-001's multi-particulate dosage formulation for oral administration as a potential treatment for Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD).

Global Urea Cycle Disorder Market: By Enzyme Deficiency Type

The ornithine transcarbamylas (OTC) segment is expected to be the largest segment in the market from 2023-2028. The market is anticipated to grow significantly as a result of factors such as product approvals, rising number of R&D projects, and rising number of strategic initiatives taken by key market players to promote OTC. Ornithine transcarbamylase deficiency is one of the most prevalent disorders across the globe.

Global Urea Cycle Disorder Market: By Route of Administration

By route of administration, the global urea cycle disorder market is further bifurcated into oral and injectable. The oral segment is anticipated to be the largest segment in the market from 2023-2028 due to the widespread use of this method of medication administration and due to its added advantages such as ease of use, safety, high affordability, and usability as compared to the latter one. Moreover, formally medications in most of the cases, are taken orally to either have a local effect on the alimentary canal or a systemic effect after being absorbed into the bloodstream.

asia pacific urea cycle disorder market

Global Urea Cycle Disorder Market: By Region

North America is expected to have the largest share in the market from 2023 to 2028. This is mainly due to the presence of key UCD related pharmaceutical players across U.S., the growth in the number of research and development projects associated with UCD drugs and nutrients, and the high prevalence of urea cycle disorders. It is also anticipated that increasing product launch activities and other growth strategic initiatives like alliances and mergers will aid in the market's expansion in the region.

Asia Pacific is expected to be the fastest growing segment in the global market. Some of the factors supporting the growth of this region are the presence of well-established pharma companies, rising expenditure for R&D activities by industry titans in the pharmaceutical sector, and partnerships between pharmaceutical, biotech companies and research institutes.

Global Urea Cycle Disorder Market Share and Competitor Analysis

The key players covered in the global urea cycle disorder market report include Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories among others.

Please note: This is not an exhaustive list of companies profiled in the report.

1          STRATEGIC INSIGHTS ON NEW REVENUE POCKETS

1.1    Strategic Opportunity & Attractiveness Analysis

1.1.1        Hot Revenue Pockets

1.1.2        Market Attractiveness Score

1.1.3        Revenue Impacting Opportunity

1.1.4        High Growing Region/Country

1.1.5        Competitor Analysis

1.1.6        Consumer Analysis

1.2    Global Market Estimates' View

1.3    Strategic Insights across Business Functions

1.3.1        For Chief Executive Officers

1.3.2        For Chief Marketing Officers

1.3.3        For Chief Strategy Officers

1.4    Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into

2          TECHNOLOGICAL TRENDS

2.1   Technological Adoption Rate

2.2   Current Trend Impact Analysis

2.3   Future Trend Impact Analysis

2.4   Data Metrics on Feed Stocks

3          GLOBAL MARKET OUTLOOK

3.1   Market Pyramid Analysis

3.1.1        Introduction

3.1.2        Adjacent Market Opportunities

3.1.3        Ancillary Market Opportunities

3.2   Demand Side Analysis

3.2.1        Market Drivers: Impact Analysis

3.2.2        Market Restraints: Impact Analysis

3.2.3        Market Opportunities: Impact Analysis

3.2.4        Market Challenges: Impact Analysis

3.3   Supply Side Analysis

3.3.1        Porter’s Five Forces Analysis

3.3.1.1 Threat of New Entrants

3.3.1.2 Threat of New Substitutes

3.3.1.3 Bargaining Power of Suppliers

3.3.1.4 Bargaining Power of Buyers

3.3.1.5 Intensity of Competitive Rivalry

3.3.2        SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)

3.3.2.1 Political Landscape

3.3.2.2 Economic Landscape

3.3.2.3 Social Landscape

3.3.2.4 Technology Landscape

3.3.3        Value Chain Analysis

3.3.4        Trend Analysis

3.3.5        Gap Analysis

3.3.6        Cost Analysis

4          GLOBAL UREA CYCLE DISORDER, BY TREATMENT TYPE

4.1   Introduction

4.2   Urea Cycle Disorder: Treatment Type Scope Key Takeaways

4.3   Revenue Growth Analysis, 2022 & 2028

4.4   Amino Acid Supplements

4.4.1        Amino Acid Supplements Market Estimates and Forecast, 2020-2028 (USD Million)

4.5   Sodium Phenylbutyrate

4.5.1        Sodium Phenylbutyrate Market Estimates and Forecast, 2020-2028 (USD Million)

4.6   Glycerol Phenylbutyrate

4.7.1        Glycerol Phenylbutyrate Market Estimates and Forecast, 2020-2028 (USD Million)

4.7   Sodium Benzoate

4.7.1           Sodium Benzoate Market Estimates and Forecast, 2020-2028 (USD Million)

4.8   Others

4.8.1           Others Market Estimates and Forecast, 2020-2028 (USD Million)

5          GLOBAL UREA CYCLE DISORDER, BY ENZYME DEFICIENCY TYPE

5.1   Introduction

5.2   Urea Cycle Disorder: Enzyme Deficiency Type Scope Key Takeaways

5.3   Revenue Growth Analysis, 2022 & 2028

5.4   Ornithine Transcarbamylas (OTC)

5.4.1        Ornithine Transcarbamylas (OTC) Market Estimates and Forecast, 2020-2028 (USD Million)

5.5   Argininosuccinate Synthetase (citrullinemia) (AS)

5.5.1        Argininosuccinate Synthetase (citrullinemia) (AS) Market Estimates and Forecast, 2020-2028 (USD Million)

5.6   Arginase (AG)

5.6.1        Arginase (AG) Market Estimates and Forecast, 2020-2028 (USD Million)

5.7   Argininosuccinate Lyase (AL)

5.7.1        Argininosuccinate Lyase (AL) Market Estimates and Forecast, 2020-2028 (USD Million)

5.8   Carbamoyl Phosphate Synthase (CPS1)

5.8.1        Carbamoyl Phosphate Synthase (CPS1) Market Estimates and Forecast, 2020-2028 (USD Million)

5.9   N-acetylglutamate Synthase (NAGS)

5.9.1        N-acetylglutamate Synthase (NAGS) Market Estimates and Forecast, 2020-2028 (USD Million)

6          GLOBAL UREA CYCLE DISORDER, BY ROUTE OF ADMINISTRATION

6.1   Introduction

6.2   Urea Cycle Disorder: Route of Administration Scope Key Takeaways

6.3   Revenue Growth Analysis, 2022 & 2028

6.4   Oral

6.4.1        Oral Market Estimates and Forecast, 2020-2028 (USD Million)

6.5   Injectable

6.5.1        Injectable Market Estimates and Forecast, 2020-2028 (USD Million)

7          GLOBAL UREA CYCLE DISORDER, BY REGION

7.1   Introduction

7.2   North America Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.2.1        By Treatment Type

7.2.2        By Enzyme Deficiency Type

7.2.3        By Route of Administration

7.2.4        By Country

7.2.4.1     U.S. Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.1.1        By Treatment Type

7.2.4.1.2        By Enzyme Deficiency Type

7.2.4.1.3        By Route of Administration

7.2.4.2     Canada Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.2.1        By Treatment Type

7.2.4.2.2        By Enzyme Deficiency Type

7.2.4.2.3        By Route of Administration

7.2.4.3     Mexico Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.3.1        By Treatment Type

7.2.4.3.2        By Enzyme Deficiency Type

7.2.4.3.3        By Route of Administration

7.3   Europe Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.3.1        By Treatment Type

7.3.2        By Enzyme Deficiency Type

7.3.3        By Route of Administration

7.3.4        By Country

7.3.4.1     Germany Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.1.1        By Treatment Type

7.3.4.1.2        By Enzyme Deficiency Type

7.3.4.1.3        By Route of Administration

7.3.4.2     U.K. Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.2.1        By Treatment Type

7.3.4.2.2        By Enzyme Deficiency Type

7.3.4.2.3        By Route of Administration

7.3.4.3     France Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.3.1        By Treatment Type

7.3.4.3.2        By Enzyme Deficiency Type

7.3.4.3.3        By Route of Administration

7.3.4.4     Italy Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.4.1        By Treatment Type

7.3.4.4.2        By Enzyme Deficiency Type

7.2.4.4.3        By Route of Administration

7.3.4.5     Spain Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.5.1        By Treatment Type

7.3.4.5.2        By Enzyme Deficiency Type

7.2.4.5.3        By Route of Administration

7.3.4.6     Netherlands Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.7.1        By Treatment Type

7.3.4.7.2        By Enzyme Deficiency Type

7.2.4.7.3        By Route of Administration

7.3.4.7     Rest of Europe Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.7.1        By Treatment Type

7.3.4.7.2        By Enzyme Deficiency Type

7.2.4.7.3        By Route of Administration

7.4   Asia Pacific Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.1        By Treatment Type

7.4.2        By Enzyme Deficiency Type

7.4.3        By Route of Administration

7.4.4        By Country

7.4.4.1     China Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.1.1        By Treatment Type

7.4.4.1.2        By Enzyme Deficiency Type

7.4.4.1.3        By Route of Administration

7.4.4.2     Japan Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.2.1        By Treatment Type

7.4.4.2.2        By Enzyme Deficiency Type

7.4.4.2.3        By Route of Administration

7.4.4.3     India Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.3.1        By Treatment Type

7.4.4.3.2        By Enzyme Deficiency Type

7.4.4.3.3        By Route of Administration

7.4.4.4     South Korea Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.4.1        By Treatment Type

7.4.4.4.2        By Enzyme Deficiency Type

7.4.4.4.3        By Route of Administration

7.4.4.5     Singapore Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.5.1        By Treatment Type

7.4.4.5.2        By Enzyme Deficiency Type

7.4.4.5.3        By Route of Administration

7.4.4.6     Malaysia Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.7.1        By Treatment Type

7.4.4.7.2        By Enzyme Deficiency Type

7.4.4.7.3        By Route of Administration

7.4.4.7     Thailand Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.7.1        By Treatment Type

7.4.4.7.2        By Enzyme Deficiency Type

7.4.4.7.3        By Route of Administration

7.4.4.8     Indonesia Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.8.1        By Treatment Type

7.4.4.8.2        By Enzyme Deficiency Type

7.4.4.8.3        By Route of Administration

7.4.4.9     Vietnam Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.9.1        By Treatment Type

7.4.4.9.2        By Enzyme Deficiency Type

7.4.4.9.3        By Route of Administration

7.4.4.10  Taiwan Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.10.1 By Treatment Type

7.4.4.10.2 By Enzyme Deficiency Type

7.4.4.10.3 By Route of Administration

7.4.4.11  Rest of Asia Pacific Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.11.1 By Treatment Type

7.4.4.11.2 By Enzyme Deficiency Type

7.4.4.11.3 By Route of Administration

7.5   Middle East & Africa Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.5.1        By Treatment Type

7.5.2        By Enzyme Deficiency Type

7.5.3        By Route of Administration

7.5.4        By Country

7.5.4.1     Saudi Arabia Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.1.1        By Treatment Type

7.5.4.1.2        By Enzyme Deficiency Type

7.5.4.1.3        By Route of Administration

7.5.4.2     U.A.E. Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.2.1        By Treatment Type

7.5.4.2.2        By Enzyme Deficiency Type

7.5.4.2.3        By Route of Administration

7.5.4.3     Israel Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.3.1        By Treatment Type

7.5.4.3.2        By Enzyme Deficiency Type

7.5.4.3.3        By Route of Administration

7.5.4.4     South Africa Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.4.1        By Treatment Type

7.5.4.4.2        By Enzyme Deficiency Type

7.5.4.4.3        By Route of Administration

7.5.4.5     Rest of Middle East & Africa Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.5.1        By Treatment Type

7.5.4.5.2        By Enzyme Deficiency Type

7.5.4.5.2        By Route of Administration

7.6   Central & South America Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.7.1        By Treatment Type

7.7.2        By Enzyme Deficiency Type

7.7.3        By Route of Administration

7.7.4        By Country

7.7.4.1     Brazil Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.7.4.1.1        By Treatment Type

7.7.4.1.2        By Enzyme Deficiency Type

7.7.4.1.3        By Route of Administration

7.7.4.2     Argentina Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.7.4.2.1        By Treatment Type

7.7.4.2.2        By Enzyme Deficiency Type

7.7.4.2.3        By Route of Administration

7.7.4.3     Chile Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.7.4.3.1        By Treatment Type

7.7.4.3.2        By Enzyme Deficiency Type

7.7.4.3.3        By Route of Administration

7.7.4.4     Rest of Central & South America Urea Cycle Disorder Estimates and Forecast, 2020-2028 (USD Million)

7.7.4.4.1        By Treatment Type

7.7.4.4.2        By Enzyme Deficiency Type

7.7.4.4.3        By Route of Administration

8          COMPETITIVE LANDCAPE

8.1   Company Market Share Analysis

8.2   Four Quadrant Positioning Matrix

8.2.1        Market Leaders

8.2.2        Market Visionaries

8.2.3        Market Challengers

8.2.4        Niche Market Players

8.3   Vendor Landscape

8.3.1        North America

8.3.2        Europe

8.3.3        Asia Pacific

8.3.4        Rest of the World

8.4   Company Profiles  

8.4.1        Bausch Health Companies Inc.

8.4.1.1 Business Description & Financial Analysis

8.4.1.2 SWOT Analysis

8.4.1.3 Products & Services Offered

8.4.1.4 Strategic Alliances between Business Partners

8.4.2        Recordati Rare Diseases

8.4.2.1 Business Description & Financial Analysis

8.4.2.2 SWOT Analysis

8.4.2.3 Products & Services Offered

8.4.2.4 Strategic Alliances between Business Partners

8.4.3        Eurocept Pharmaceuticals Holding (Lucane Pharma SA)

8.4.3.1 Business Description & Financial Analysis

8.4.3.2 SWOT Analysis

8.4.3.3 Products & Services Offered

8.4.3.4 Strategic Alliances between Business Partners

8.4.4        Acer Therapeutics

8.4.4.1 Business Description & Financial Analysis

8.4.4.2 SWOT Analysis

8.4.4.3 Products & Services Offered

8.4.4.4 Strategic Alliances between Business Partners

8.4.5        Ultragenyx Pharmaceutical

8.4.5.1 Business Description & Financial Analysis

8.4.5.2 SWOT Analysis

8.4.5.3 Products & Services Offered

8.4.5.4 Strategic Alliances between Business Partners

8.4.6        Aeglea BioTherapeutics

8.4.7.1 Business Description & Financial Analysis

8.4.7.2 SWOT Analysis

8.4.7.3 Products & Services Offered

8.4.7.4 Strategic Alliances between Business Partners

8.4.7        Arcturus Therapeutics, Inc.  

8.4.7.1 Business Description & Financial Analysis

8.4.7.2 SWOT Analysis

8.4.7.3 Products & Services Offered

8.4.8.4 Strategic Alliances between Business Partners

8.4.8        Orpharma Pty Ltd.

8.4.8.1 Business Description & Financial Analysis

8.4.8.2 SWOT Analysis

8.4.8.3 Products & Services Offered

8.4.8.4 Strategic Alliances between Business Partners

8.4.9        Selecta Biosciences, Inc

8.4.9.1 Business Description & Financial Analysis

8.4.9.2 SWOT Analysis

8.4.9.3 Products & Services Offered

8.4.9.4 Strategic Alliances between Business Partners

8.4.10       Abbott Laboratories

8.4.10.1 Business Description & Financial Analysis

8.4.10.2 SWOT Analysis

8.4.10.3 Products & Services Offered

8.4.10.4 Strategic Alliances between Business Partners

8.4.11      Other Companies

8.4.11.1 Business Description & Financial Analysis

8.4.11.2 SWOT Analysis

8.4.11.3 Products & Services Offered

8.4.11.4 Strategic Alliances between Business Partners

9          RESEARCH METHODOLOGY

9.1   Market Introduction

9.1.1        Market Definition

9.1.2        Market Scope & SegSodium Phenylbutyratetation

9.2   Information ProcureSodium Phenylbutyratet

9.2.1        Secondary Research

9.2.1.1 Purchased Databases

9.2.1.2 GMEs Internal Data Repository

9.2.1.3 Secondary Resources & Third Party Perspectives

9.2.1.4 Company Information Sources

9.2.2        Primary Research

9.2.2.1 Various Enzyme Deficiency Type of Respondents for Primary Interviews

9.2.2.2 Number of Interviews Conducted throughout the Research Process

9.2.2.3 Primary Stakeholders

9.2.2.4 Discussion Guide for Primary Participants

9.2.3        Expert Panels

9.2.3.1 Expert Panels Across 30+ Industry

9.2.4        Paid Local Experts

9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region

9.3   Market Estimation

9.3.1        Top-Down Approach

9.3.1.1 Macro-Economic Indicators Considered

9.3.1.2 Micro-Economic Indicators Considered

9.3.2        Bottom Up Approach

9.3.2.1 Company Share Analysis Approach

9.3.2.2 Estimation of Potential Product Sales

9.4   Data Triangulation

9.4.1        Data Collection

9.4.2        Time Series, Cross Sectional & Panel Data Analysis

9.4.3        Cluster Analysis

9.5   Analysis and Output

9.5.1        Inhouse AI Based Real Time Analytics Tool

9.5.2        Output From Desk & Primary Research

9.6   Research Assumptions & Limitations

9.7.1        Research Assumptions

9.7.2        Research Limitations

LIST OF TABLES

1 Global Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Mllion)

2 Amino Acid Supplements Market, By Region, 2020-2028 (USD Mllion)        

3 Sodium Phenylbutyrate Market, By Region, 2020-2028 (USD Mllion)          

4 Glycerol Phenylbutyrate Market, By Region, 2020-2028 (USD Mllion)      

5 Sodium Benzoate Market, By Region, 2020-2028 (USD Mllion)

6 others Market, By Region, 2020-2028 (USD Mllion)

7 Global Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Mllion)

8 Ornithine Transcarbamylas (OTC) Market, By Region, 2020-2028 (USD Mllion)    

9 Argininosuccinate Synthetase (citrullinemia) (AS) Market, By Region, 2020-2028 (USD Mllion)

10 Arginase (AG) Market, By Region, 2020-2028 (USD Mllion)

11 Argininosuccinate Lyase (AL) Market, By Region, 2020-2028 (USD Mllion)

12 Carbamoyl Phosphate Synthase (CPS1) Market, By Region, 2020-2028 (USD Mllion)

13 N-acetylglutamate Synthase (NAGS) Market, By Region, 2020-2028 (USD Mllion)

14 Global Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Mllion)

15 Oral Market, By Region, 2020-2028 (USD Mllion)    

16 Injectable Market, By Region, 2020-2028 (USD Mllion)        

17 Regional Analysis, 2020-2028 (USD Mllion)

18 North America Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

19 North America Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

20 North America Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

21 North America Urea Cycle Disorder, By Country, 2020-2028 (USD Million)

22 U.S Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

23 U.S Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

24 U.S Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

25 Canada Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

26 Canada Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

27 Canada Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

28 Mexico Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

29 Mexico Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

30 Mexico Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

31 Europe Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

32 Europe Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

33 Europe Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

34 Germany Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

35 Germany Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

36 Germany Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

37 UK Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

38 UK Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

39 UK Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

40 France Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

41 France Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

42 France Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

43 Italy Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

44 Italy Urea Cycle Disorder, By T Enzyme Deficiency Type Type, 2020-2028 (USD Million)

45 Italy Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

46 Spain Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

47 Spain Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

48 Spain Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

49 Rest Of Europe Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

50 Rest Of Europe Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

51 Rest of Europe Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

52 Asia Pacific Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

53 Asia Pacific Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

54 Asia Pacific Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

55 Asia Pacific Urea Cycle Disorder, By Country, 2020-2028 (USD Million)

56 China Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

57 China Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

58 China Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

59 India Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

60 India Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

61 India Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

62 Japan Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

63 Japan Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

64 Japan Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

65 South Korea Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

66 South Korea Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

67 South Korea Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

68 Middle East & Africa Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

69 Middle East & Africa Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

70 Middle East & Africa Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

71 Middle East & Africa Urea Cycle Disorder, By Country, 2020-2028 (USD Million)

72 Saudi Arabia Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

73 Saudi Arabia Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

74 Saudi Arabia Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

75 UAE Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

76 UAE Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

77 UAE Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

78 Central & South America Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

79 Central & South America Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

80 Central & South America Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

81 Central & South America Urea Cycle Disorder, By Country, 2020-2028 (USD Million)

82 Brazil Urea Cycle Disorder, By Treatment Type, 2020-2028 (USD Million)

83 Brazil Urea Cycle Disorder, By Enzyme Deficiency Type, 2020-2028 (USD Million)

84 Brazil Urea Cycle Disorder, By Route of Administration, 2020-2028 (USD Million)

85 Bausch Health Companies Inc.: Products & Services Offering

86 Recordati Rare Diseases: Products & Services Offering 

87 Eurocept Pharmaceuticals Holding (Lucane Pharma SA): Products & Services Offering           

88 Acer Therapeutics: Products & Services Offering

89 Ultragenyx Pharmaceutical: Products & Services Offering          

90 AEGLEA BIOTHERAPEUTICS: Products & Services Offering    

91 Arcturus Therapeutics, Inc. : Products & Services Offering         

92 Orpharma Pty Ltd.: Products & Services Offering

93 Selecta Biosciences, Inc, Inc: Products & Services Offering        

94  Abbott Laboratories: Products & Services Offering         

95 Other Companies: Products & Services Offering  

LIST OF FIGURES

1 Global Urea Cycle Disorder Overview

2 Global Urea Cycle Disorder Value From 2020-2028 (USD Mllion)

3 Global Urea Cycle Disorder Share, By Treatment Type (2022)

4 Global Urea Cycle Disorder Share, By Enzyme Deficiency Type (2022)

5 Global Urea Cycle Disorder Share, By Route of Administration (2022)

6 Global Urea Cycle Disorder, By Region (Asia Pacific Market)

7 Technological Trends In Global Urea Cycle Disorder

8 Four Quadrant Competitor Positioning Matrix

9 Impact Of Macro & Micro Indicators On The Market

10 Impact Of Key Drivers On The Global Urea Cycle Disorder

11 Impact Of Challenges On The Global Urea Cycle Disorder

12 Porter’s Five Forces Analysis

13 Global Urea Cycle Disorder: By Treatment Type Scope Key Takeaways

14 Global Urea Cycle Disorder, By Treatment Type Segment: Revenue Growth Analysis

15 Amino Acid Supplements Market, By Region, 2020-2028 (USD Mllion)

16 Sodium Phenylbutyrate Market, By Region, 2020-2028 (USD Mllion)

17 Glycerol Phenylbutyrate Market, By Region, 2020-2028 (USD Mllion)

18 Sodium Benzoate Market, By Region, 2020-2028 (USD Mllion)        

19 Others Market, By Region, 2020-2028 (USD Mllion)    

20 Global Urea Cycle Disorder: By Enzyme Deficiency Type Scope Key Takeaways

21 Global Urea Cycle Disorder, By Enzyme Deficiency Type Segment: Revenue Growth Analysis

22 Ornithine Transcarbamylas (OTC) Market, By Region, 2020-2028 (USD Mllion)   

23 Argininosuccinate Synthetase (citrullinemia) (AS) Market, By Region, 2020-2028 (USD Mllion)

24 Arginase (AG) Market, By Region, 2020-2028 (USD Mllion)

25 Argininosuccinate Lyase (AL) Market, By Region, 2020-2028 (USD Mllion)

26 Carbamoyl Phosphate Synthase (CPS1) Market, By Region, 2020-2028 (USD Mllion)

27 N-acetylglutamate Synthase (NAGS) Market, By Region, 2020-2028 (USD Mllion)

28 Global Urea Cycle Disorder: By Route of Administration Scope Key Takeaways

29 Global Urea Cycle Disorder, By Route of Administration Segment: Revenue Growth Analysis

30 Oral Market, By Region, 2020-2028 (USD Mllion)        

31 Injectable Market, By Region, 2020-2028 (USD Mllion)          

32 Regional Segment: Revenue Growth Analysis

33 Global Urea Cycle Disorder: Regional Analysis

34 North America Urea Cycle Disorder Overview

35 North America Urea Cycle Disorder, By Treatment Type

36 North America Urea Cycle Disorder, By Enzyme Deficiency Type

37 North America Urea Cycle Disorder, By Route of Administration

38 North America Urea Cycle Disorder, By Country

39 U.S. Urea Cycle Disorder, By Treatment Type

40 U.S. Urea Cycle Disorder, By Enzyme Deficiency Type

41 U.S. Urea Cycle Disorder, By Route of Administration

42 Canada Urea Cycle Disorder, By Treatment Type

43 Canada Urea Cycle Disorder, By Enzyme Deficiency Type

44 Canada Urea Cycle Disorder, By Route of Administration

45 Mexico Urea Cycle Disorder, By Treatment Type

46 Mexico Urea Cycle Disorder, By Enzyme Deficiency Type

47 Mexico Urea Cycle Disorder, By Route of Administration

48 Four Quadrant Positioning Matrix

49 Company Market Share Analysis

50 Bausch Health Companies Inc.: Company Snapshot

51 Bausch Health Companies Inc.: SWOT Analysis

52 Bausch Health Companies Inc.: Geographic Presence

53 Recordati Rare Diseases: Company Snapshot

54 Recordati Rare Diseases: SWOT Analysis

55 Recordati Rare Diseases: Geographic Presence

56 Eurocept Pharmaceuticals Holding (Lucane Pharma SA): Company Snapshot

57 Eurocept Pharmaceuticals Holding (Lucane Pharma SA): SWOT Analysis

58 Eurocept Pharmaceuticals Holding (Lucane Pharma SA): Geographic Presence

59 Acer Therapeutics: Company Snapshot

60 Acer Therapeutics: Swot Analysis

61 Acer Therapeutics: Geographic Presence

62 Ultragenyx Pharmaceutical: Company Snapshot

63 Ultragenyx Pharmaceutical: SWOT Analysis

64 Ultragenyx Pharmaceutical: Geographic Presence

65 Aeglea BioTherapeutics: Company Snapshot

66 Aeglea BioTherapeutics: SWOT Analysis

67 Aeglea BioTherapeutics: Geographic Presence

68 Arcturus Therapeutics, Inc. : Company Snapshot

69 Arcturus Therapeutics, Inc. : SWOT Analysis

70 Arcturus Therapeutics, Inc. : Geographic Presence

71 Orpharma Pty Ltd.: Company Snapshot

72 Orpharma Pty Ltd.: SWOT Analysis

73 Orpharma Pty Ltd.: Geographic Presence

74 Selecta Biosciences, Inc, Inc.: Company Snapshot

75 Selecta Biosciences, Inc, Inc.: SWOT Analysis

76 Selecta Biosciences, Inc, Inc.: Geographic Presence

77 Abbott Laboratories: Company Snapshot

78 Abbott Laboratories: SWOT Analysis

79 Abbott Laboratories: Geographic Presence

80 Other Companies: Company Snapshot

81 Other Companies: SWOT Analysis

82 Other Companies: Geographic Presence

The Global Urea Cycle Disorder Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Urea Cycle Disorder Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.
This website is secure and your personal details are safe. Privacy
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The global urea cycle disorder market is expected to be valued at USD 2.56 billion in 2023, and is projected to grow at a CAGR of 3.6% from 2023 to 2028.
The key players covered in the urea cycle disorder market report are Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories among others.
The opportunities prevailing in the global urea cycle disorder market are the strategic initiatives including collaborations, expansions, and acquisitions, and rising prevalence of urea cycle disorders amongst both new-borns and geriatric patients.
The severity of the urea cycle disorder (UCD) is determined by the defective amount of protein. The presence of well-established companies, an increase in R&D spending by industry titans in the pharmaceutical sector and collaborations between pharmaceutical and biotech companies and research institutes, are some of the factors influencing the global market for urea cycle disorders.

Tailor made solutions just for you

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

OUR CLIENTS

  • Client of Global Market Estimates - Fedex
  • Client of Global Market Estimates - Samsung
  • Client of Global Market Estimates - Siemens
  • Client of Global Market Estimates - Lonza
  • Client of Global Market Estimates - DuPont
  • Client of Global Market Estimates - Medtronic
  • Client of Global Market Estimates - Toray
  • Client of Global Market Estimates - Signify
  • Client of Global Market Estimates - Teledyne
  • Client of Global Market Estimates - Trelleborg
  • Client of Global Market Estimates - Kikkoman Biochemifa
  • Client of Global Market Estimates - Leoni
  • Client of Global Market Estimates - Molnlycke
  • Client of Global Market Estimates - Spirent
  • Client of Global Market Estimates - Tokyo Electron Limited
  • Client of Global Market Estimates - Aranca
  • Client of Global Market Estimates - Asahi Kasei
  • Client of Global Market Estimates - Chimai
  • Client of Global Market Estimates - Grapsud
  • Client of Global Market Estimates - Horiba
  • Client of Global Market Estimates - Indorama
  • Client of Global Market Estimates - L&T
  • Client of Global Market Estimates - Integralife
  • Client of Global Market Estimates - Synamedia
  • Client of Global Market Estimates - Sorrento Therapeutics
  • Client of Global Market Estimates - Solenis
  • Client of Global Market Estimates - Sartorius